Meta Platforms and Microsoft are aggressively investing in artificial intelligence.
2 extracted signals · 2 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 20 Sept 2025, 19:45 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The video provides a fundamental analysis comparing META and MSFT, focusing on revenue growth, operating cash flow, and return on invested capital. META's revenue has increased nearly 10x since 2015, reaching $179 billion with 4 billion monthly active users. Microsoft's revenue has risen from $94 billion in 2015 to $282 billion, partially attributed to acquisitions. META's operating cash flow to sales ratio is 57.2%, higher than Microsoft's 48.3%, though Microsoft shows notable improvement. META's return on invested capital is 34.8%, while Microsoft's is 21.8%. A discounted cash flow model estimates META's intrinsic value at $819.99 (current market price $780.25) and Microsoft at $461.28 (current market price $508.45). Based on forward price to operating cash flow, META is rated as a buy and expected to outperform Microsoft.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

